PharmaLive: NeurogesX to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
May 17th, 2008 | by admin |SAN MATEO, Calif., May 15, 2008 /PRNewswire-FirstCall/ — NeurogesX, Inc. , a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present on Monday, May 19, 2008 at the Rodman & Renshaw 5th Annual Global Healthcare Conference. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions.
Event: Rodman & Renshaw 5th Annual Global Healthcare Conference
Date: Monday, May 19, 2008
Time: 5:15 p.m. CEST
Place: Le Meridien Beach Plaza Hotel, Monte Carlo, Monaco
An audio Web cast of the Company’s presentations will be available by going to the investor relations section of NeurogesX’ Web site at www.neurogesx.com. A replay of the presentation will be available for 15 days.
About NeurogesX, Inc.
NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX’ late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. NeurogesX’ marketing authorization application (MAA) to the European Medicines Agency (EMEA) was accepted for review in September 2007 and NeurogesX plans to file a new drug application (NDA) with the United States Food and Drug Administration (FDA) in 2008 for PHN.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX’ potential products, including its lead product candidate NGX-4010. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, NeurogesX’ product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX- 4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX’ business, investors should consult NeurogesX’ filings with the Securities and Exchange Commission.
NeurogesX
Stephen Ghiglieri
(650) 358-3310
sghiglieri@neurogesx.com
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
scarrington@theruthgroup.com
jrando@theruthgroup.com
CONTACT: Stephen Ghiglieri of NeurogesX, +1-650-358-3310,; or Investors, Stephanie Carrington,+1-646-536-7017, , or Media, Jason Rando,+1-646-536-7025, , both of The Ruth Group forNeurogesX sghiglieri@neurogesx.com scarrington@theruthgroup.com jrando@theruthgroup.com
Web site: http://www.neurogesx.com/
Ticker Symbol: (NASDAQ-NMS:NGSX)
Terms and conditions of use apply
Copyright © 2008 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Stumble it!